ViAqua develops RNA-i formulated drug delivery technology for aquaculture, offering orally administered treatments that prevent viral epidemics in aquaculture. Its proprietary RNAi nanoparticle formulation is delivered via feed or immersion, triggering cell reactions to disable viral infections. Founded in 2014 in Rehovot, Israel, the company has raised $12.6M in Series A funding from investors including Rabo Ventures, Nutreco, and S2G Investments. Developer of RNA-i formulated drug delivery technology for aquaculture. The company has developed orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics. Its drug delivery platform uses proprietary RNAi nanoparticle formulation which is delivered via feed or immersion to produce and triggers a cell reaction to disable the viral infection.
ViAqua
Series AViAqua develops RNA-i formulated drug delivery technology for aquaculture, offering orally administered treatments that prevent viral epidemics in aquaculture. Its proprietary RNAi nanoparticle formulation is delivered via feed or immersion, triggering cell reactions to disable viral infections. Founded in 2014 in Rehovot, Israel, the company has raised $12.6M in Series A funding from investors including Rabo…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation,
Aquaculture Tech > Health Management > Disease Management > Oral Vaccines
Team background
College Wise > Tel Aviv University
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.